OncoGenex Takes Over Cancer Drug From Isis
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II-stage chemo booster is now fully funded by Vancouver firm.
You may also be interested in...
OncoGenex Aims To Move OGX-011 Into Phase III For Hormone Refractory Prostate Cancer In Early 2009
Firm reports the investigational antisense cancer drug shows survival benefit when combined with docetaxel and prednisone.
OncoGenex Aims To Move OGX-011 Into Phase III For Hormone Refractory Prostate Cancer In Early 2009
Firm reports the investigational antisense cancer drug shows survival benefit when combined with docetaxel and prednisone.
Sonus, OncoGenex Merge Into Specialty Oncology Company
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.